Companies › Avenzo Therapeutics
4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AVZO-021 CDK2 inhibitor | CDK2 | Phase 1 | Advanced Solid Tumor; HR+/HER2- Breast Cancer | Jan 2028 |
| AVZO-023 CDK4 inhibitor | CDK4 | Phase 1 | HR+/HER2- Breast Cancer | Aug 2028 |
| AVZO-103 | – | Phase 1 | Solid Tumor Cancer | Mar 2030 |
| AVZO-1418 | – | Phase 1 | Solid Tumor Cancer | Jun 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05867251 | AVZO-021 | Phase 1 | Advanced Solid Tumor | Oncology | Jan 2028 |
| NCT06998407 | AVZO-023 | Phase 1 | HR+/HER2- Breast Cancer | Oncology | Aug 2028 |
| NCT06998407 | AVZO-021 | Phase 1 | HR+/HER2- Breast Cancer | Oncology | Aug 2028 |
| NCT07193511 | AVZO-103 | Phase 1 | Solid Tumor Cancer | Oncology | Mar 2030 |
| NCT07038343 | AVZO-1418 | Phase 1 | Solid Tumor Cancer | Oncology | Jun 2030 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.